Analysis of Recurrence Risk After Radical Surgery for Differentiated Thyroid Carcinoma Based on Fibroblast Growth Factor Receptor 4 and Inflammatory Cytokines
Abstract
Objective: This study aimed to evaluate the synergistic role of fibroblast growth factor receptor 4 (FGFR4) and inflammatory cytokines (interleukin-6 [IL-6], tumor necrosis factor-α [TNF-α], and C-reactive protein [CRP]) in predicting recurrence of differentiated thyroid carcinoma (DTC) after radical surgery, and to develop a combined predictive model for improved postoperative risk stratification.
Methods: We enrolled 102 DTC patients treated between February 2022 and January 2024, along with 98 healthy controls. Serum levels of FGFR4, IL-6, TNF-α, and CRP were measured preoperatively and postoperatively using ELISA. Independent risk factors were identified through logistic regression, diagnostic performance was assessed using ROC analysis, and correlations of FGFR4 and inflammatory cytokines with postoperative recurrence were evaluated.
Results: Preoperative levels of FGFR4, IL-6, TNF-α, and CRP were significantly elevated in DTC patients compared to healthy controls (P<0.05). A diagnostic model integrating these four markers demonstrated superior performance (AUC=0.931; sensitivity 94.12%, specificity 79.59%) over individual biomarkers (P<0.05). Among DTC patients, those with recurrence (n=26) exhibited significantly higher FGFR4 and inflammatory cytokine levels than the non-recurrent group (P<0.05). The combined model predicted 1-year recurrence with an AUC of 0.864 (sensitivity 73.08%, specificity 93.42%).
Conclusion: The synergistic interaction between FGFR4 and inflammatory cytokines plays a critical role in DTC. Their combined detection enhances postoperative recurrence risk prediction, offering a valuable tool for clinical risk stratification.
Copyright (c) 2025 Yingying Sha, Yongjie Hu, Peifei Huang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.